HEMOSTATIC PARAMETERS IN SEPSIS PATIENTS TREATED WITH ANTI-TNF±-MONOCLONAL ANTIBODIES
- 1 October 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Shock
- Vol. 6 (4) , 233-237
- https://doi.org/10.1097/00024382-199610000-00001
Abstract
Tumor necrosis factor-± (TNF±) is a central mediator in the pathogenesis of sepsis. It also interferes with the hemostatic system and exerts a net procoagulant effect. Since TNFa may contribute to thrombotic complications in sepsis patients, we determined markers of thrombin activation, parameters of the fibrinolytic system (D-dimer, tissue plasminogen activator antigen (tPA), urinary type plasminogen activator antigen (uPA), plasminogen activator inhibitor antigen (PAI-1)) and von Willebrand factor antigen (vWF) in 30 patients with sepsis or septic shock. All patients were treated with standard therapy, but 14 patients were treated additionally with an anti-TNF± monoclonal antibody (MAK 195F); 16 patients served as historical controls. No significant effect of the antibody on the parameters of the hemostatic system could be determined. Our data speak against a modulation of coagulation or the fibrinolytic system by the monoclonal anti-TNF± antibody MAK 195F in this cohort of sepsis patients.Keywords
This publication has 0 references indexed in Scilit: